2024-02-11 02:33:00
(Seoul = Yonhap News) Reporter Lee Joo-young = Research results have shown that erectile dysfunction treatment can reduce the risk of Alzheimer’s disease by up to 18%. Randomized controlled clinical trials including both men and women are needed to generalize these results, the researchers said.
Dr. Ruth Brouwer’s team at University College London (UCL) in the UK confirmed this link between erectile dysfunction medication and Alzheimer’s disease by following up 270,000 men diagnosed with erectile dysfunction in the American Academy of Neurology’s journal Neurology on the 8th. revealed.
“While progress is being made in treatments to remove amyloid plaques from the brains of patients with early-stage Alzheimer’s disease, there is a pressing need for treatments that prevent or delay the disease,” said Dr. Brouwer. “These results are encouraging and demonstrate the need for further research.”
The research team studied 269,725 men (average age 59 years) diagnosed with erectile dysfunction in the UK between 2004 and 2017 and examined the relationship between taking the erectile dysfunction treatment drug phosphodiesterase 5 inhibitor (PDE5I) and developing Alzheimer’s disease. Follow-up was conducted for an average of 5 years.
The participants had no problems with memory or thinking at the start of the study, 55% were prescribed erectile dysfunction medication, and 45% were not prescribed medication. PDE5I, which was initially developed as a treatment for high blood pressure by dilating blood vessels and improving blood flow, is currently used as a treatment for erectile dysfunction.
A total of 1,119 people were diagnosed with Alzheimer’s disease during the study period. 749 people in the group taking PDE5I developed Alzheimer’s disease, and 370 people in the group not taking PDE5I.
The incidence rate was analyzed to be 8.1 people per 10,000 person-years (one person-year is the value of observing one person for one year) in the group taking the treatment, and 9.7 people in the group not taking the treatment.
When the research team adjusted for other factors that can affect the incidence of Alzheimer’s disease, such as age, smoking status, and amount of alcohol consumed, it was found that people who took erectile dysfunction medication had an 18% lower chance of developing Alzheimer’s disease than people who did not take erectile dysfunction medication.
Additionally, the prevention effect was found to be greater for those who issued more prescriptions. If the number of prescriptions issued was 21 to 50, the risk of developing the disease was 44% lower than that of non-users, and if the number of prescriptions issued was 50 or more, it was 35% lower.
“More research is needed to validate these results and elucidate the drug’s potential benefits, mechanism of action, and optimal dosage,” said Dr. Brouwer. “We need to conduct a randomized controlled clinical trial,” he said.
◆ 출처 : Neurology, Ruth Brauer et al., ‘Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease’, https://www.neurology.org/doi/10.1212/WNL.0000000000209131
<저작권자(c) 연합뉴스, 무단 전재-재배포, AI 학습 및 활용 금지>
1707622145
#Erectile #dysfunction #treatment #lowers #risk #Alzheimers #disease